Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia
- Focus Registrational; Therapeutic Use
- Acronyms ROMANA-2
- Sponsors Helsinn Therapeutics
- 07 Jun 2022 Results of this post-hoc analysis from ROMANA 1 and 2 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2020 Results of a post hoc analysis of data pooled from ROMANA 1and 2studies assessing anorexia symptoms and concerns reported by pts with advanced non-small cell lung cancer and cachexia on the basis of their BMI and weight loss degree, presented at the 45th European Society for Medical Oncology Congress
- 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 assessing the baseline characteristics of patients with mGPS 0-2 presented at the 42nd European Society for Medical Oncology Congress